Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Cash & Equivalents (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Cash & Equivalents for 11 consecutive years, with $13.7 million as the latest value for Q1 2025.

  • On a quarterly basis, Cash & Equivalents rose 21.18% to $13.7 million in Q1 2025 year-over-year; TTM through Mar 2025 was $13.7 million, a 21.18% increase, with the full-year FY2024 number at $19.2 million, up 27.01% from a year prior.
  • Cash & Equivalents was $13.7 million for Q1 2025 at Marker Therapeutics, down from $19.2 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $64.5 million in Q1 2021 to a low of $6.4 million in Q1 2023.
  • A 5-year average of $24.2 million and a median of $17.8 million in 2022 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 98.34% in 2021, then tumbled 72.18% in 2022.
  • Marker Therapeutics' Cash & Equivalents stood at $42.4 million in 2021, then crashed by 72.18% to $11.8 million in 2022, then grew by 28.26% to $15.1 million in 2023, then increased by 27.01% to $19.2 million in 2024, then fell by 28.65% to $13.7 million in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Cash & Equivalents are $13.7 million (Q1 2025), $19.2 million (Q4 2024), and $9.0 million (Q3 2024).